This study aims to compare the diagnostic performance of 18F-FDG and 18F-FSPG PET/CT in lung, breast, and abdominal cancers before undergoing therapy. In addition, the role of 18F-FSPG PET/CT in evaluating therapy response and prognosis will also be evaluated.
Study Type
OBSERVATIONAL
Enrollment
120
National Taiwan University Hospital
Taipei, Taiwan
RECRUITINGStaging ability of 18F-FSPG PET/CT
Sensitivity, specificity, diagnostic accuracy of 18F-FSPG and 18F-FDG PET/CT will be compared according to patient-based and lesion-based analysis using paired t-test or Krusal-Wallis test.
Time frame: 3 years
Ability of 18F-FSPG PET/CT in therapy response evaluation and prognosis prediction
Comparison between 18F-FSPG and 18F-FDG PET/CT will be done using both qualitative and quantitative measures
Time frame: 3 years
Uptake of 18F-FSPG
Standardised uptake values (SUV) will be compared between 18F-FSPG and 18F-FDG
Time frame: 3 years
Safety of 18F-FSPG PET/CT
Number of reported adverse events
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.